Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Filters

My NCBI Filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
1989 2
1990 3
1991 2
1992 3
1995 3
1996 3
1997 4
1998 5
1999 6
2000 1
2001 1
2002 3
2003 7
2004 2
2005 4
2006 4
2007 4
2008 5
2009 12
2010 7
2011 8
2012 10
2013 12
2014 24
2015 20
2016 7
2017 15
2018 9
2019 11
2020 15
2021 17
2022 10
2023 1
2024 0

Text availability

Article attribute

Article type

Publication date

Similar articles for PMID: 24395436

205 results

Results by year

Filters applied: . Clear all
Page 1
Pharmacogenetically based dosing of thiopurines in childhood acute lymphoblastic leukemia: influence on cure rates and risk of second cancer.
Levinsen M, Rotevatn EØ, Rosthøj S, Nersting J, Abrahamsson J, Appell ML, Bergan S, Bechensteen AG, Harila-Saari A, Heyman M, Jonsson OG, Maxild JB, Niemi M, Söderhäll S, Schmiegelow K; Nordic Society of Paediatric Haematology, Oncology. Levinsen M, et al. Pediatr Blood Cancer. 2014 May;61(5):797-802. doi: 10.1002/pbc.24921. Epub 2014 Jan 3. Pediatr Blood Cancer. 2014. PMID: 24395436
Methotrexate/6-mercaptopurine maintenance therapy influences the risk of a second malignant neoplasm after childhood acute lymphoblastic leukemia: results from the NOPHO ALL-92 study.
Schmiegelow K, Al-Modhwahi I, Andersen MK, Behrendtz M, Forestier E, Hasle H, Heyman M, Kristinsson J, Nersting J, Nygaard R, Svendsen AL, Vettenranta K, Weinshilboum R; Nordic Society for Paediatric Haematology and Oncology. Schmiegelow K, et al. Blood. 2009 Jun 11;113(24):6077-84. doi: 10.1182/blood-2008-11-187880. Epub 2009 Feb 17. Blood. 2009. PMID: 19224761 Free PMC article.
The circadian schedule for childhood acute lymphoblastic leukemia maintenance therapy does not influence event-free survival in the NOPHO ALL92 protocol.
Clemmensen KK, Christensen RH, Shabaneh DN, Harila-Saari A, Heyman M, Jonsson OG, Wesenberg F, Rosthøj S, Schmiegelow K; Nordic Society of Pediatric Hematology, Oncology (NOPHO). Clemmensen KK, et al. Pediatr Blood Cancer. 2014 Apr;61(4):653-8. doi: 10.1002/pbc.24867. Epub 2013 Nov 22. Pediatr Blood Cancer. 2014. PMID: 24265159 Clinical Trial.
No association between relapse hazard and thiopurine methyltransferase geno- or phenotypes in non-high risk acute lymphoblastic leukemia: a NOPHO ALL2008 sub-study.
Nielsen SN, Toksvang LN, Grell K, Nersting J, Abrahamsson J, Lund B, Kanerva J, Jónsson ÓG, Vaitkeviciene G, Pruunsild K, Appell ML, Hjalgrim LL, Schmiegelow K. Nielsen SN, et al. Cancer Chemother Pharmacol. 2021 Aug;88(2):271-279. doi: 10.1007/s00280-021-04281-7. Epub 2021 Apr 29. Cancer Chemother Pharmacol. 2021. PMID: 33928426
Thiopurine methyltransferase activity is related to the risk of relapse of childhood acute lymphoblastic leukemia: results from the NOPHO ALL-92 study.
Schmiegelow K, Forestier E, Kristinsson J, Söderhäll S, Vettenranta K, Weinshilboum R, Wesenberg F; Nordic Society of Paediatric Haematology and Oncology. Schmiegelow K, et al. Leukemia. 2009 Mar;23(3):557-64. doi: 10.1038/leu.2008.316. Epub 2008 Nov 6. Leukemia. 2009. PMID: 18987654 Free PMC article. Clinical Trial.
Oral methotrexate/6-mercaptopurine may be superior to a multidrug LSA2L2 Maintenance therapy for higher risk childhood acute lymphoblastic leukemia: results from the NOPHO ALL-92 study.
Schmiegelow K, Heyman M, Kristinsson J, Mogensen UB, Rosthøj S, Vettenranta K, Wesenberg F, Saarinen-Pihkala U; Nordic Society of Paediatric Haematology and Oncology (NOPHO). Schmiegelow K, et al. J Pediatr Hematol Oncol. 2009 Jun;31(6):385-92. doi: 10.1097/MPH.0b013e3181a6e171. J Pediatr Hematol Oncol. 2009. PMID: 19648786 Clinical Trial.
Thiopurine S-methyltransferase (TPMT) polymorphisms in children with acute lymphoblastic leukemia, and the need for reduction or cessation of 6-mercaptopurine doses during maintenance therapy: the Polish multicenter analysis.
Peregud-Pogorzelski J, Tetera-Rudnicka E, Kurzawski M, Brodkiewicz A, Adrianowska N, Mlynarski W, Januszkiewicz D, Drozdzik M. Peregud-Pogorzelski J, et al. Pediatr Blood Cancer. 2011 Oct;57(4):578-82. doi: 10.1002/pbc.23013. Epub 2011 Feb 11. Pediatr Blood Cancer. 2011. PMID: 21319286
Myelotoxicity after high-dose methotrexate in childhood acute leukemia is influenced by 6-mercaptopurine dosing but not by intermediate thiopurine methyltransferase activity.
Levinsen M, Rosthøj S, Nygaard U, Heldrup J, Harila-Saari A, Jonsson OG, Bechensteen AG, Abrahamsson J, Lausen B, Frandsen TL, Weinshilboum RM, Schmiegelow K. Levinsen M, et al. Cancer Chemother Pharmacol. 2015 Jan;75(1):59-66. doi: 10.1007/s00280-014-2613-7. Epub 2014 Oct 28. Cancer Chemother Pharmacol. 2015. PMID: 25347948 Free PMC article.
Individualized toxicity-titrated 6-mercaptopurine increments during high-dose methotrexate consolidation treatment of lower risk childhood acute lymphoblastic leukaemia. A Nordic Society of Paediatric Haematology and Oncology (NOPHO) pilot study.
Frandsen TL, Abrahamsson J, Lausen B, Vettenranta K, Heyman M, Behrentz M, Castor A, Wehner PS, Frost BM, Andersen EW, Schmiegelow K. Frandsen TL, et al. Br J Haematol. 2011 Oct;155(2):244-7. doi: 10.1111/j.1365-2141.2011.08835.x. Epub 2011 Aug 18. Br J Haematol. 2011. PMID: 21848519 Free article. Clinical Trial.
205 results